Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480399 | 0.75 | — | — | |
| SCHEMBL4497824 | 0.65 | LMNA (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL18858519 | 0.64 | NOS3 (0.44) | NOS3NOS1NOS2ESR1ESR2 | |
| SCHEMBL5138610 | 0.60 | ADRA2A (0.34) | — | |
| SCHEMBL2321830 | 0.59 | LMNA (0.37) | — | |
| SCHEMBL18647537 | 0.58 | NOS3 (0.39) | NOS3NOS1NOS2ESR1ESR2 | |
| SCHEMBL18858521 | 0.58 | NOS3 (0.40) | NOS3NOS1NOS2ESR1ESR2 | |
| SCHEMBL2326805 | 0.58 | CNR2 (0.39) | — | |
| SCHEMBL18858540 | 0.57 | NOS3 (0.46) | NOS3NOS1NOS2ESR1ESR2 | |
| SCHEMBL19561516 | 0.57 | CNR2 (0.34) | ESR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044034-B1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | HOFFMANN LA ROCHE (CH) | 2012-08-22 | — | — | EP | claimed |
| US-7547697-B2 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-06-16 | — | — | US | claimed |
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | claimed |
| EP-2044034-B1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | HOFFMANN LA ROCHE (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7547697-B2 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | NOS3 2458/4885NOS1 1604/4885NOS2 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.